Studies have shown that ESR1-mutant breast cancers may harbour other alterations, including elevated PI3K/AKT pathway activation, amplification of cyclin D1, together with increased growth factor signalling via FGF and ERBB receptors31,43. This evidence concerns the gene ESR1 and breast carcinoma.